Ernexa Therapeutics (ERNAW) Cash from Restructuring (2021)

Ernexa Therapeutics (ERNAW) has 1 years of Cash from Restructuring data on file, last reported at $5.8 million in Q1 2021.

• Quarterly Cash from Restructuring changed N/A year-over-year to $5.8 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $5.8 million (changed N/A YoY) and the FY2021 annual result came in at $5.8 million, changed N/A from the prior year.
• Cash from Restructuring held at $5.8 million in Q1 2021.
• In the past five years, Cash from Restructuring ranged from a high of $5.8 million in Q1 2021 to a low of $5.8 million in Q1 2021.